Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials

Journal of Perinatology volume 29, pages S23–S28 (2009)Cite this article

Abstract

The benefits of exogenous synthetic or animal-derived surfactants for prevention or treatment of respiratory distress syndrome (RDS) are well established. Data from head-to-head trials comparing animal-derived surfactants primarily with the synthetic surfactant colfosceril suggest that the major clinical advantages afforded by the presence of surfactant protein (SP)-B and SP-C in animal-derived preparations relate to faster onset of action, a reduction in the incidence of RDS when used prophylactically, and a lower incidence of air leaks and RDS-related deaths. However, no benefits in terms of overall mortality or BPD have been shown in these head-to-head comparisons. Findings from trials of a new-generation synthetic surfactant containing a peptide that mimics SP-B, as well as their follow-up study suggest that its administration improves short-term clinical outcomes compared with colfosceril and results in survival through 1 year of age, which is at least comparable, if not perhaps superior, to that seen with animal-derived surfactants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ainsworth SB, Milligan DW . Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am J Respir Med 2002; 1: 417–433.

    Article  CAS  PubMed  Google Scholar 

  2. Soll RF, Blanco F . Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001; (2) Art. No.: CD000144.

  3. Curstedt T, Jörnvall H, Robertson B, Bergman T, Berggren P . Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem 1987; 168: 255–262.

    Article  CAS  PubMed  Google Scholar 

  4. Notter RH, Wang Z, Egan EA, Holm BA . Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002; 114: 21–34.

    Article  CAS  PubMed  Google Scholar 

  5. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 1995; 92: 7794–7798.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93: 1860–1863.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nogee LM, Dunbar III AE, Wert SE, Askin F, Hamvas A, Whitsett JA . Brief report: a mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573–579.

    Article  CAS  PubMed  Google Scholar 

  8. Cochrane CG, Revak SD . Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991; 254: 566–568.

    Article  CAS  PubMed  Google Scholar 

  9. Moya F, Maturana A . Animal-derived surfactants versus past and present synthetic surfactants: current status. Clin Perinatol 2007; 34: 145–177.

    Article  PubMed  Google Scholar 

  10. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123: 757–766.

    Article  CAS  PubMed  Google Scholar 

  11. Sehgal SS, Ewing CK, Richards T, Taeusch HW . Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994; 86: 46–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97: 1–6.

    Google Scholar 

  13. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV . Comparative efficacy of Exosurf and Survanta on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997; 17: 455–460.

    CAS  PubMed  Google Scholar 

  14. da Costa DE, Pai MGK, Al Kusaiby SM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol 1999; 27: 312–317.

    Article  CAS  PubMed  Google Scholar 

  15. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A et al., for the International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018–1029.

    Article  PubMed  Google Scholar 

  16. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings J, Jung AL et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100: 39–50.

    Article  CAS  PubMed  Google Scholar 

  17. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396–406.

    Article  CAS  PubMed  Google Scholar 

  18. Kukkonen AK, Virtanen M, Järvenpää A-L, Pokela ML, Ikonen S, Fellman V . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000; 89: 556–561.

    Article  CAS  PubMed  Google Scholar 

  19. Ainsworth SB, Beresford MW, Milligan DWA, Shaw N, Matthews J, Fenton A et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25 to 29 weeks' gestation: a randomised trial. Lancet 2000; 355: 1387–1392.

    Article  CAS  PubMed  Google Scholar 

  20. Andersson S, Kheiter A, Merritt TA . Oxidative inactivation of surfactants. Lung 1999; 177: 179–189.

    Article  CAS  PubMed  Google Scholar 

  21. Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996; 39: 715–724.

    Article  CAS  PubMed  Google Scholar 

  22. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404–410.

    Article  CAS  PubMed  Google Scholar 

  23. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al., for the Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030–1038.

    Article  PubMed  Google Scholar 

  24. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C et al. SELECT and STAR Study Investigators. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter, randomized, controlled trials. Pediatrics 2007; 119: e1361–e1370.

    Article  PubMed  Google Scholar 

  25. Kattwinkel J . Synthetic surfactants: the search goes on. Pediatrics 2005; 115: 1075–1076.

    Article  PubMed  Google Scholar 

  26. Halliday HH . Surfactants: past, present and future. J Perinatol 2008; 28: S47–S56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Engle WA, the Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419–432.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neonatology, New Hanover Regional Medical Center, Wilmington, NC, USA

    F Moya

  2. Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA

    F Moya

Authors
  1. F Moya
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to F Moya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moya, F. Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials. J Perinatol 29 (Suppl 2), S23–S28 (2009). https://doi.org/10.1038/jp.2009.26

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/jp.2009.26

Keywords

This article is cited by

Search

Advanced search

Quick links